Small molecule · Inhibitor of HDAC1 · developed by Tango Therapeutics
TNG260 is an orally bioavailable small molecule that binds the CoREST complex and inhibits the catalytic activity of HDAC1. Its inhibition increases histone acetylation and alters gene expression, with potential to reverse immune evasion linked to STK11 loss-of-function mutations. It is studied in non-small cell lung cancer and solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05887492 | Phase 1/2 | Non Small Cell Lung Cancer | Active not recruiting | TNGX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Lung AdenocarcinomaLung CancerNon Small Cell Lung CancerSolid Tumors, Adult
Updated Nov 1, 2026. Something wrong or missing? Report it on the TNGX page.
See TNGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TNGX catalysts and pipeline →